Antimalarial preclinical drug development: a single oral dose of a 5‐carbon‐linked trioxane dimer plus mefloquine cures malaria‐infected mice | Zendy

Moon Deuk Kyu | Zendy; Singhal Vandana | Zendy; Kumar Nirbhay | Zendy; Shapiro Theresa A. | Zendy; Posner Gary H. | Zendy

Premium

Antimalarial preclinical drug development: a single oral dose of a 5‐carbon‐linked trioxane dimer plus mefloquine cures malaria‐infected mice

Author(s) -

Moon Deuk Kyu,

Singhal Vandana,

Kumar Nirbhay,

Shapiro Theresa A.,

Posner Gary H.

Publication year - 2010

Publication title -

drug development research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.582

H-Index - 60

eISSN - 1098-2299

pISSN - 0272-4391

DOI - 10.1002/ddr.20350

Subject(s) - trioxane , mefloquine , artemisinin , pharmacology , dimer , drug , chemistry , malaria , antimalarial agent , artemether , hydrochloride , oral administration , medicine , chloroquine , plasmodium falciparum , organic chemistry , immunology , copolymer , polymer

Three new 5‐carbon‐linked trioxane dimer carboxylate esters have been prepared from the natural trioxane, artemisinin, in only three steps and 40–50% overall yields. Each one of these new chemical entities is at least as efficacious as the clinically used trioxane antimalarial drug artemether when combined with mefloquine hydrochloride in a low single oral dose cure. Drug Dev Res 71: 76–81, 2010. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research